脑胶质瘤靶向治疗前景可观。
Targeted Options for Glioma Looking Good.
出版信息
Cancer Discov. 2023 Aug 4;13(8):1755. doi: 10.1158/2159-8290.CD-ND2023-0004.
Abstract
According to the phase III INDIGO trial, vorasidenib, an IDH1/2 inhibitor, significantly benefited adults with IDH1/2-mutant low-grade gliomas, reducing progression risk and delaying the need for chemoradiotherapy. Meanwhile, in a pediatric low-grade glioma cohort of FIREFLY-1, a phase II trial, robust responses to the type II pan-RAF inhibitor tovorafenib were seen.
摘要
根据 III 期 INDIGO 试验结果，IDH1/2 抑制剂ivosidenib 显著改善了 IDH1/2 突变型低级别胶质瘤成人患者的预后，降低了疾病进展风险并延缓了放化疗的需求。与此同时，在 FIREFLY-1 儿科低级别胶质瘤队列的一项 II 期试验中，观察到 II 型泛 RAF 抑制剂 tovorafenib 对该类患者产生了显著的治疗应答。
Zotero 插件